Guys, the EU are currently negotiating a free-trade agreement with India, and some of the provisions could damage the generics industry in India. For example, Indian regulators may have to conduct their own tests on Cipla finasteride before it can be approved. Also, according to this Guardian article, 'the deal would allow the validity of patents to be extended', which to me suggests that Merck might be able to enforce their Propecia patent in India...The deal is due by the end of the year so maybe a bulk buy from Inhouse to see us through until 2013 is in order? Keep your eyes peeled for updates anyway...there's at least a small chance that it'll get a lot harder to get generic finasteride before the end of the year...
http://www.guardian.co.uk/world/2010/ju ... trade-deal
http://www.guardian.co.uk/world/2010/ju ... trade-deal